PDCD1 and hepatocellular carcinoma: Sun et al. (2020) found no significant correlation between clinical outcomes and HBV loads in HCC patients receiving the PD-1 inhibitor. In addition, Yuan et al. (2021) found that HBV loads did not affect the short-term efficacy of the PD-1 inhibitor combined with antiangiogenic therapy for HCC patients.